Incyte Corp
INCY102.920USD
+1.350+1.33%
Close 11/04, 16:00（ET）Quotes delayed by 15 min
20.19BMarket Cap
16.98P/E TTM
More Details of Incyte Corp Company
Incyte Corporation is a biopharmaceutical company, which is focused on the discovery, development, and commercialization of therapeutics. The Company operates in two therapeutic areas. One therapeutic area is Hematology/Oncology, which is comprised of Myeloproliferative Neoplasms and Graft-Versus-Host Disease, as well as solid tumors and hematologic malignancies. Its other therapeutic area is Inflammation and Autoimmunity, which includes its Dermatology commercial franchise. Its hematology and oncology franchise are comprised of six products, which are JAKAFI (ruxolitinib), MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab), PEMAZYRE (pemigatinib), ICLUSIG (ponatinib), NIKTIMVO (axatilimab-csfr), and ZYNYZ (retifanlimab-dlwr), as well as numerous clinical development programs. The Company's pipeline also includes two first-in-class small molecule antagonist of Mas-related G protein-coupled receptor (MRGPRX2) and INCB000547, an oral MRGPRX4 antagonist.
Incyte Corp Info
Ticker SymbolINCY
Company nameIncyte Corp
IPO dateDec 06, 1993
CEOMr. Bill Meury
Number of employees2617
Security typeOrdinary Share
Fiscal year-endDec 06
Address1801 Augustine Cut-Off
CityWILMINGTON
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code19803
Phone13024986700
Websitehttps://www.incyte.com/
Ticker SymbolINCY
IPO dateDec 06, 1993
CEOMr. Bill Meury
Company Executives of Incyte Corp
Name
Name/Position
Position
Shareholding
Change
Mr. Herve Hoppenot
Mr. Herve Hoppenot
Director
Director
1.62M
-3.14%
Mr. Julian C. Baker
Mr. Julian C. Baker
Independent Chairman of the Board
Independent Chairman of the Board
278.77K
--
Mr. Paul J. Clancy
Mr. Paul J. Clancy
Independent Director
Independent Director
147.17K
+0.19%
Mr. Jean-Jacques Bienaime ,
Mr. Jean-Jacques Bienaime ,
Independent Director
Independent Director
144.77K
+1.77%
Mr. Michael James Morrissey
Mr. Michael James Morrissey
Executive Vice President, Head - Global Technical Operations
Executive Vice President, Head - Global Technical Operations
86.16K
+5.70%
Dr. Katherine A. High, M.D.
Dr. Katherine A. High, M.D.
Independent Director
Independent Director
66.08K
+3.96%
Dr. Otis W. Brawley, M.D.
Dr. Otis W. Brawley, M.D.
Independent Director
Independent Director
50.10K
+5.29%
Dr. Susanne Schaffert, Ph.D.
Dr. Susanne Schaffert, Ph.D.
Independent Director
Independent Director
37.95K
+4.60%
Dr. Pablo J. Cagnoni
Dr. Pablo J. Cagnoni
President - Research and Development
President - Research and Development
35.48K
+62.39%
Mr. Lee Heeson
Mr. Lee Heeson
Executive Vice President - Incyte, International
Executive Vice President - Incyte, International
32.31K
-1.41%
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Herve Hoppenot
Mr. Herve Hoppenot
Director
Director
1.62M
-3.14%
Mr. Julian C. Baker
Mr. Julian C. Baker
Independent Chairman of the Board
Independent Chairman of the Board
278.77K
--
Mr. Paul J. Clancy
Mr. Paul J. Clancy
Independent Director
Independent Director
147.17K
+0.19%
Mr. Jean-Jacques Bienaime ,
Mr. Jean-Jacques Bienaime ,
Independent Director
Independent Director
144.77K
+1.77%
Mr. Michael James Morrissey
Mr. Michael James Morrissey
Executive Vice President, Head - Global Technical Operations
Executive Vice President, Head - Global Technical Operations
86.16K
+5.70%
Dr. Katherine A. High, M.D.
Dr. Katherine A. High, M.D.
Independent Director
Independent Director
66.08K
+3.96%
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
By BusinessUSD
Name
Revenue
Proportion
JAKAFI revenues
763.79M
62.84%
OPZELURA revenues
164.50M
13.53%
JAKAVI product royalty revenues
109.71M
9.03%
NIKTIMVO revenues
36.15M
2.97%
OLUMIANT product royalty revenues
33.48M
2.75%
Other
107.89M
8.88%
No Data
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
JAKAFI revenues
763.79M
62.84%
OPZELURA revenues
164.50M
13.53%
JAKAVI product royalty revenues
109.71M
9.03%
NIKTIMVO revenues
36.15M
2.97%
OLUMIANT product royalty revenues
33.48M
2.75%
Other
107.89M
8.88%
Shareholding Stats
Updated: Wed, Oct 22
Updated: Wed, Oct 22
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Baker Bros. Advisors LP
15.66%
The Vanguard Group, Inc.
10.21%
Dodge & Cox
7.43%
BlackRock Institutional Trust Company, N.A.
5.95%
State Street Investment Management (US)
5.03%
Other
55.71%
Shareholders
Shareholders
Proportion
Baker Bros. Advisors LP
15.66%
The Vanguard Group, Inc.
10.21%
Dodge & Cox
7.43%
BlackRock Institutional Trust Company, N.A.
5.95%
State Street Investment Management (US)
5.03%
Other
55.71%
Shareholder Types
Shareholders
Proportion
Investment Advisor/Hedge Fund
38.63%
Investment Advisor
37.21%
Hedge Fund
20.76%
Pension Fund
2.95%
Individual Investor
2.17%
Research Firm
2.06%
Bank and Trust
1.47%
Sovereign Wealth Fund
0.77%
Family Office
0.29%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
1419
203.92M
103.87%
-180.79K
2025Q2
1423
201.60M
103.23%
-197.50K
2025Q1
1457
199.01M
102.81%
-12.15M
2024Q4
1448
191.80M
99.11%
-19.23M
2024Q3
1401
192.85M
100.02%
-35.92M
2024Q2
1385
209.06M
108.78%
-39.98M
2024Q1
1357
227.85M
101.54%
-21.15M
2023Q4
1323
228.89M
102.19%
-14.49M
2023Q3
1300
224.25M
100.13%
-17.63M
2023Q2
1306
220.30M
98.76%
-17.67M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Baker Bros. Advisors LP
30.74M
15.74%
+256.17K
+0.84%
Jun 30, 2025
The Vanguard Group, Inc.
20.05M
10.27%
+134.71K
+0.68%
Jun 30, 2025
Dodge & Cox
14.60M
7.47%
-269.15K
-1.81%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
11.69M
5.99%
-228.50K
-1.92%
Jun 30, 2025
State Street Investment Management (US)
9.88M
5.06%
-159.70K
-1.59%
Jun 30, 2025
AQR Capital Management, LLC
8.20M
4.2%
+1.47M
+21.75%
Jun 30, 2025
Geode Capital Management, L.L.C.
4.35M
2.23%
+139.74K
+3.32%
Jun 30, 2025
Renaissance Technologies LLC
3.88M
1.99%
+173.20K
+4.67%
Jun 30, 2025
LSV Asset Management
3.86M
1.98%
+223.86K
+6.15%
Jun 30, 2025
Invesco Capital Management LLC
2.96M
1.52%
+218.65K
+7.97%
Jun 30, 2025
View more
Related ETFs
Updated: Mon, Oct 6
Updated: Mon, Oct 6
Name
Proportion
iShares Genomics Immunology and Healthcare ETF
4.92%
First Trust NYSE Arca Biotechnology Index Fund
4%
Invesco Biotechnology & Genome ETF
3.34%
SPDR S&P Biotech ETF
2.86%
VanEck Biotech ETF
2.39%
Bushido Capital US Equity ETF
2.34%
Strategas Global Policy Opportunities ETF
2.31%
Innovator IBD Breakout Opportunities ETF
2.2%
Virtus LifeSci Biotech Products ETF
2.04%
Invesco S&P 500 Equal Weight Health Care ETF
2.02%
View more
iShares Genomics Immunology and Healthcare ETF
Proportion4.92%
First Trust NYSE Arca Biotechnology Index Fund
Proportion4%
Invesco Biotechnology & Genome ETF
Proportion3.34%
SPDR S&P Biotech ETF
Proportion2.86%
VanEck Biotech ETF
Proportion2.39%
Bushido Capital US Equity ETF
Proportion2.34%
Strategas Global Policy Opportunities ETF
Proportion2.31%
Innovator IBD Breakout Opportunities ETF
Proportion2.2%
Virtus LifeSci Biotech Products ETF
Proportion2.04%
Invesco S&P 500 Equal Weight Health Care ETF
Proportion2.02%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
